Jerzy Trojan

Cancer Immunogene Therapy

Anti ¿ gene anti IGF-I approach. Case of Glioblastoma

• Broschiertes Buch

Produktbeschreibung

Certain specific antigens, which behave as oncoproteins, are present in normal fetal/neonatal developing brain. It was demonstrated that a convergence exists between ontogenesis and onco-genesis. The most malignant example of central nervous system neoplasia is glioblastoma multiforme. The biomarker - oncoprotein - characteristic of glial fetal and tumoral cells, but not neuronal cells, is IGF-I. For this reason, for therapy purpose, the arrest of IGF-I synthesis in cancer glial cells of glioblastoma was performed using in vitro anti - gene anti IGF-I strategy (IGF-I antisense /triple helix, AS/TH). The created AS/TH cells, became immunogenic and expressed MHC-I, B71 antigens. The AS/TH cells while injected in glioblastoma patients, induced the antitumor immune response and stopped the progression of tumor development. The survival of treated glioblastoma patients reached 2 years, and in some cases, up to 3-4 years. The established Anti - Gene IGF-I cancer immunotherapy was introduced in USA, Europe, China and Latin America.

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Seitenzahl: 140
• Erscheinungstermin: 4. April 2017
• Englisch
• Abmessung: 220mm x 150mm x 9mm
• Gewicht: 227g
• ISBN-13: 9783330063457
• ISBN-10: 3330063459
• Artikelnr.: 48133707

Autorenporträt

Jerzy Trojan has completed his Habilitation (Doctorat d¿Etat es Sciences) in 1981 in Paris VI University, and joined in 1984 INSERM. He is a co-author of 218 publications (Research Gate profile 2017). Between 1993-2017 he has established cancer immunogene therapy as a new oncology domain (Trojan et al, Science 1993; Wikipedia, Gene therapy, 2017)